THERAPY ACCELERATION PROGRAM® (TAP)
Strategic Venture Philanthropy Funding Initiative Since 2007
SARS-CoV2 TAP Initiative Apply by March 31
What is TAP?
TAP is a strategic venture philanthropy funding initiative to accelerate high-risk, innovative blood cancer therapeutics and change the standard of care in leukemia, lymphoma, and multiple myeloma.
Since its establishment in 2007, TAP has invested more than $120 million in over 60 projects.
Portfolio
Currently over 20 TAP-supported companies or institutions with assets in active development.
TAP Team
Over 50 years of first-hand experience in bringing value to your organization beyond the funding with our critical research insight.
Latest News
Read all about the exciting news and milestone events happening with our current and former TAP partners.
How can TAP benefit your company?
Hear what the SVP of Corporate & Business Development of Stemline Therapeutics has to say about TAP and the value created for his company beyond the funding amount. LLS TAP partnered with Stemline in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Since 2017, three TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA):
CPX-351 (Vyxeos®), first approved treatment (an innovative reformulation of two chemotherapies) for patients with certain types of high-risk acute myeloid leukemia (AML) - approved on August 3 2017 with clinical data published in Journal of Clinical Oncology
Axicabtagene ciloleucel (Yescarta®), first CAR T-cell immunotherapy approved for patients with non-Hodgkin lymphoma (NHL) and transformed follicular lymphoma (tFL) - approved on October 18 2017 with clinical data published in Lancet Oncology
Tagraxofusp-erzs (Elzonris®), first approved therapy for children and adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN) - approved on August 3 2017 with clinical data published in New England Journal of Medicine
Currently, there are over 20 TAP-supported companies or institutions with assets in active development, including 5 ongoing or planned registration-enabling clinical studies.
“LLS’s selection of mavorixafor for TAP collaboration and investment reinforces its potential as a novel therapy for Waldenström’s macroglobulinemia. Approximately 30 to 40 percent of WM patients have a CXCR4 mutation, and a number of these patients do not respond well to current therapies. We look forward to working closely with Dr. Greenberger [LLS CSO] and the LLS TAP team to gain valuable data and insights throughout the upcoming clinical trial as we work to bring a new therapeutic option to patients with this rare form of cancer.”
- Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals
View archived TAP webcasts and programs
- Value Creation for Companies: Dollars & Beyond (Archived December 2020)
- LLS Research Now: LLS’s Venture Philanthropy Model for Accelerating Promising Therapies (Archived October 2020)
- LLS Business Networking Reception ASH 2019 (Archived December 2019)
"We are very pleased to be partnering with The Leukemia & Lymphoma Society. This partnership constitutes not only a significant validation of the high potential of SEL120 in treatment of AML patients, but also offers a unique opportunity to work with world renowned researchers, specialists in the field of hematological cancers, increasing the chances of bringing a breakthrough treatment to the patients whose treatment options currently remain very limited."